Financing
Stock Issuance Proceeds
Alnylam Pharmaceuticals Stock Issuance Proceeds decreased by 68.4% to $13.16M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 73.3%, from $49.37M to $13.16M.
Analysis
StatementCash Flow Statement
SectionFinancing
CategoryCapital Allocation
SignalContext dependent
VolatilityStable
First reportedQ4 2013
Last reportedQ4 2025
How to read this metric
Higher proceeds typically indicate increased employee participation in equity incentive plans, while lower proceeds may reflect reduced option exercise activity.
Detailed definition
Reflects the cash inflows received from the issuance of common stock, primarily driven by employee stock option exercise...
Peer comparison
Standard line item for companies with significant equity-based compensation programs for staff and management.
Metric ID:
proceeds_from_stock_issuanceHistorical Data
20 periods
| Q2 '21 | Q3 '21 | Q4 '21 | Q1 '22 | Q2 '22 | Q3 '22 | Q4 '22 | Q1 '23 | Q2 '23 | Q3 '23 | Q4 '23 | Q1 '24 | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $81.86M | $72.39M | -$201.23M | $27.12M | $22.50M | $153.02M | $56.71M | $42.37M | $49.39M | $24.81M | $30.89M | $25.86M | $132.78M | $108.04M | $36.28M | $49.37M | $81.22M | $77.74M | $41.70M | $13.16M |
| QoQ Change | — | -11.6% | -378.0% | +113.5% | -17.0% | +580.0% | -62.9% | -25.3% | +16.6% | -49.8% | +24.5% | -16.3% | +413.5% | -18.6% | -66.4% | +36.1% | +64.5% | -4.3% | -46.4% | -68.4% |
| YoY Change | — | — | — | — | -72.5% | +111.4% | +128.2% | +56.2% | +119.5% | -83.8% | -45.5% | -39.0% | +168.8% | +335.5% | +17.4% | +90.9% | -38.8% | -28.0% | +14.9% | -73.3% |
Range-$201.23M – $153.02M
CAGR-31.9%
Avg YoY Growth+41.4%
Median YoY Growth+16.2%
Current Streak3 quarters decline
Stock Issuance Proceeds at Other Companies
Frequently Asked Questions
- What is Alnylam Pharmaceuticals's stock issuance proceeds?
- Alnylam Pharmaceuticals (ALNY) reported stock issuance proceeds of $13.16M in Q1 2026.
- How has Alnylam Pharmaceuticals's stock issuance proceeds changed year-over-year?
- Alnylam Pharmaceuticals's stock issuance proceeds decreased by 73.3% year-over-year, from $49.37M to $13.16M.
- What does stock issuance proceeds mean?
- Cash received from the sale of company stock to employees or investors.